Advanced HF No Obstacle to AF Ablation Success: CASTLE-HTx Advanced HF No Obstacle to AF Ablation Success: CASTLE-HTx
This ' should help eradicate the current somewhat nihilistic approach ' to managing atrial fibrillation in advanced heart failure, said an expert.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - August 28, 2023 Category: Transplant Surgery Tags: Cardiology News Source Type: news
Afib Ablation Exceeds Expectations in Sickest Heart Failure Patients
(MedPage Today) -- AMSTERDAM -- Catheter ablation conferred large clinical benefits to people with end-stage heart failure and symptomatic atrial fibrillation (Afib) in the small CASTLE HTx randomized trial that was terminated prematurely for... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 28, 2023 Category: Cardiology Source Type: news
CRT-D Upgrade Suits Patients With Pacing-Related Heart Failure
(MedPage Today) -- AMSTERDAM -- A cardiac resynchronization therapy (CRT) upgrade produced solid clinical benefit for patients with pacing-induced heart failure with reduced ejection fraction (HFrEF), the small BUDAPEST CRT Upgrade randomized... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - August 27, 2023 Category: Urology & Nephrology Source Type: news
Supporting Evidence for a Common Practice Supporting Evidence for a Common Practice
John Mandrola, MD, reviews BUDAPEST CRT from ESC 2023, which supports the practice of upgrading patients with pacing-induced heart failure to cardiac resynchronization therapy.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 27, 2023 Category: Cardiology Tags: Cardiology Expert Column Source Type: news
IV Iron Shows Only Modest Benefit in HF: HEART-FID IV Iron Shows Only Modest Benefit in HF: HEART-FID
The largest ever study of IV iron supplementation in patients with heart failure failed to meet a new rigorous definition of significance, and the results were generally regarded as disappointing.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 26, 2023 Category: Internal Medicine Tags: Cardiology News Source Type: news
Iron Infusions Narrowly Miss the Mark for Clinical Benefit in Heart Failure
(MedPage Today) -- AMSTERDAM -- Ferric carboxymaltose (FCM) did not go so far as to improve hard outcomes in people with heart failure with reduced ejection fraction (HFrEF) and iron deficiency in the well-powered HEART-FID trial, and it is questionable... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - August 26, 2023 Category: Urology & Nephrology Source Type: news
Semaglutide in HFpEF Cleared a Low Bar Semaglutide in HFpEF Cleared a Low Bar
Patients with heart failure with preserved ejection fraction and obesity lost weight and felt better while taking semaglutide vs placebo, but was the bar for success set too low in STEP-HFpEF?theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 26, 2023 Category: Cardiology Tags: Cardiology Expert Column Source Type: news
How Novo Nordisk, A Top 1% Stock, Just Hit Another Bull's-eye In Obesity Treatment
said Friday its obesity treatment, Wegovy, reduced symptoms and physical limitations in people whose hearts are failing. But Novo Nordisk stock remained mostly flat. The company tested Wegovy in patients with heart failure with preserved ejection fraction. This means their hearts are failing, but…#novonordisk #mikhailkosiborod #kosiborod #saintluke #kansas #elililly #lly #novo #danish #glp1 (Source: Reuters: Health)
Source: Reuters: Health - August 26, 2023 Category: Consumer Health News Source Type: news
Wegovy, the Weight Loss Drug, Relieves Heart Failure Symptoms: Drugmaker ’s Study
The drug Wegovy eased issues for people with a type of heart problem, adding to the treatment ’s benefits beyond weight loss. (Source: NYT Health)
Source: NYT Health - August 25, 2023 Category: Consumer Health News Authors: Benjamin Mueller Tags: Heart Semaglutide (Drug) Research Diabetes Obesity Weight New England Journal of Medicine Novo Nordisk A/S your-feed-healthcare Source Type: news
SGLT2 Inhibitors, Rapid Titration, IV Iron Get a Boost in New European HF Guideline
(MedPage Today) -- AMSTERDAM -- SGLT2 inhibitor therapy and other innovations in heart failure (HF) treatment were among the highlights of the updated European guidelines presented here at the European Society of Cardiology Congress and published... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - August 25, 2023 Category: Urology & Nephrology Source Type: news
How Novo Nordisk, A Top 1% Stock, Just Hit Another Bull's-eye In Obesity Treatment
Novo Nordisk said Friday its obesity treatment, Wegovy, reduced heart-failure symptoms. But Novo Nordisk stock remained flat. The post How Novo Nordisk, A Top 1% Stock, Just Hit Another Bull's-eye In Obesity Treatment appeared first on Investor's Business Daily.#novonordisk (Source: Reuters: Health)
Source: Reuters: Health - August 25, 2023 Category: Consumer Health News Source Type: news
Ozempic and Wegovy can reverse heart disease symptoms: Slimming jabs offer hopes of cure as study suggests key ingredient semaglutide is three times more effective than existing treatments
Millions of heart disease sufferers could benefit from new weight-loss jabs after a global trial found they were three times more effective than any existing treatments for heart failure. (Source: the Mail online | Health)
Source: the Mail online | Health - August 25, 2023 Category: Consumer Health News Source Type: news
Wegovy Reduces Heavy Symptom Burden of Obesity-Related Heart Failure
(MedPage Today) -- AMSTERDAM -- Semaglutide 2.4 mg (Wegovy) led to clinically meaningful reductions in symptoms and weight among patients with obesity and heart failure with preserved ejection fraction (HFpEF), the STEP-HFpEF trial showed.
While... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - August 25, 2023 Category: Urology & Nephrology Source Type: news
Wegovy May Be Valuable New Option for Heart Failure Patients
FRIDAY, Aug. 25, 2023 -- Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.
Now, injected Wegovy could prove a boon... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 25, 2023 Category: General Medicine Source Type: news
Weight-loss drug can reverse heart failure symptoms, study finds
Semaglutide injections trigger ‘very large improvements’ in patients with hearts too stiff to fill properlyWeight-loss jabs can reverse the symptoms of heart failure, according to a global trial that experts say could revolutionise treatment.Heart failure is one of the world ’s fastest growing health threats. About 65 million people have the condition, with cases soaring in recent years. However, few treatment options are available.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 25, 2023 Category: Science Authors: Andrew Gregory in Amsterdam Tags: Heart disease Medical research Drugs Obesity Science Society World news Source Type: news
